In the past week, LFCR stock has gone down by -12.37%, with a monthly decline of -12.71% and a quarterly surge of 34.00%. The volatility ratio for the week is 10.78%, and the volatility levels for the last 30 days are 7.50% for Lifecore Biomedical Inc The simple moving average for the past 20 days is -9.22% for LFCR’s stock, with a 14.21% simple moving average for the past 200 days.
Is It Worth Investing in Lifecore Biomedical Inc (NASDAQ: LFCR) Right Now?
Lifecore Biomedical Inc (NASDAQ: LFCR) has a higher price-to-earnings ratio of 111.74x compared to its average ratio, The 36-month beta value for LFCR is at 0.99. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LFCR is 32.68M, and currently, shorts hold a 7.20% of that float. The average trading volume for LFCR on January 03, 2025 was 197.50K shares.
LFCR) stock’s latest price update
Lifecore Biomedical Inc (NASDAQ: LFCR)’s stock price has dropped by -10.36 in relation to previous closing price of 7.43. Nevertheless, the company has seen a loss of -12.37% in its stock price over the last five trading days. zacks.com reported 2025-01-02 that Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.06 per share a year ago.
Analysts’ Opinion of LFCR
Many brokerage firms have already submitted their reports for LFCR stocks, with Craig Hallum repeating the rating for LFCR by listing it as a “Buy.” The predicted price for LFCR in the upcoming period, according to Craig Hallum is $8 based on the research report published on September 05, 2024 of the previous year 2024.
Stephens gave a rating of “Equal-Weight” to LFCR, setting the target price at $2 in the report published on March 20th of the previous year.
LFCR Trading at -2.80% from the 50-Day Moving Average
After a stumble in the market that brought LFCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.17% of loss for the given period.
Volatility was left at 7.50%, however, over the last 30 days, the volatility rate increased by 10.78%, as shares sank -10.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.86% upper at present.
During the last 5 trading sessions, LFCR fell by -12.37%, which changed the moving average for the period of 200-days by -7.24% in comparison to the 20-day moving average, which settled at $7.34. In addition, Lifecore Biomedical Inc saw -10.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LFCR starting from Morberg John D, who proposed sale 10,000 shares at the price of $7.17 back on Nov 20 ’24. After this action, Morberg John D now owns shares of Lifecore Biomedical Inc, valued at $71,691 using the latest closing price.
Morberg John D, the Former officer of Lifecore Biomedical Inc, proposed sale 30,990 shares at $6.64 during a trade that took place back on Nov 11 ’24, which means that Morberg John D is holding shares at $205,803 based on the most recent closing price.
Stock Fundamentals for LFCR
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.35 for the gross margin
The net margin for Lifecore Biomedical Inc stands at -0.11. The total capital return value is set at -0.07. Equity return is now at value 17.29, with 2.32 for asset returns.
Based on Lifecore Biomedical Inc (LFCR), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.52. The debt to equity ratio resting at 0.8. The interest coverage ratio of the stock is -1.86.
Currently, EBITDA for the company is 35.6 million with net debt to EBITDA at -0.33. When we switch over and look at the enterprise to sales, we see a ratio of 1.9. The receivables turnover for the company is 6.49for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.83.
Conclusion
In conclusion, Lifecore Biomedical Inc (LFCR) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
